A study to evaluate safety and feasibility of administrating Zoledronic acid to children and adolescents with acute lymphoblastic leukemia and lymphoma to prevent joint complication.

一项评估对患有急性淋巴细胞白血病和淋巴瘤的儿童和青少年服用唑来膦酸以预防关节并发症的安全性和可行性的研究。

• 批准号: nhmrc : 1075242
• 负责人: Dr Bhavna Padhye
• 金额: $ 1.08万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/study-evaluate-safety-joint-complication/455659
• 关键词: study; evaluate; safety; feasibility; administrating

Osteonecrosis (bone death) is a debilitating complication seen following chemotherapy for acute lymphoblastic leukemia in older children. It potentially could lead to destruction of joint, severely limiting quality of life and ultimately requiring joint replacement surgery. Currently there is no effective medical treatment to manage this. Based on our animal experiments we want to study if Zoledronic acid could prevent severe joint destruction in these children and improve their quality of life.

骨坏死（骨死亡）是年龄较大的儿童急性淋巴细胞白血病化疗后出现的一种使人衰弱的并发症。它可能导致关节破坏，严重限制生活质量，最终需要关节置换手术。目前还没有有效的治疗方法来控制这种情况。基于我们的动物实验，我们想研究唑来膦酸是否可以预防这些儿童严重的关节破坏并改善他们的生活质量。